The 180-day extension provides a temporary reprieve, but the transfer to the Nasdaq Capital Market signals ongoing distress. Monitor for a reverse stock split announcement or other compliance measures before the December 28, 2026 deadline. Failure to regain compliance would trigger delisting proceedings, which could severely impact liquidity and access to capital for this $26M market cap biotech.
Price Chart
Executive Summary
Barinthus Biotherapeutics received a 180-day extension from Nasdaq, until December 28, 2026, to regain compliance with the $1.00 minimum bid price requirement. The company's ADS listing was transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective July 2, 2026. Failure to regain compliance could result in delisting, though the company may pursue a reverse stock split.
Key Facts
- Nasdaq granted a 180-day extension until December 28, 2026, to regain compliance with the $1.00 minimum bid price requirement.
- Listing of ADSs transferred from Nasdaq Global Market to Nasdaq Capital Market effective July 2, 2026.
- Company received the initial deficiency notice on December 30, 2025, and the original 180-day compliance period expired June 29, 2026.
- If compliance is not regained by December 28, 2026, Nasdaq will issue a delisting notice, subject to appeal.
- All shareholder proposals at the 2026 Annual General Meeting were approved, including re-election of directors and ratification of auditors.
Financial Impact
No financial figures reported. The delisting risk is material for a $26M market cap company.
Risk Factors
- Failure to regain compliance by December 28, 2026, could lead to delisting from Nasdaq.
- A reverse stock split, if pursued, may not be approved by shareholders or may not achieve the desired price level.
- Continued listing on the Nasdaq Capital Market (vs. Global Market) may reduce institutional visibility and liquidity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-080308 |
| Document: 0001104659-26-080308-index-headers.html | 0001104659-26-080308 |
| Document: 0001104659-26-080308-index.html | 0001104659-26-080308 |
| Document: 0001104659-26-080308.txt | 0001104659-26-080308 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 6w ago | EFFECT | $0.7400 | awaiting T+20 | — | — |
Aug 25, 2026 9w ago | 8-K | $0.6600 | awaiting T+20 | — | — |
Jul 2, 2026 16w ago | 8-K | $0.6201 $0.5570 | ▲ +10.18% | ▲ +9.76% | — |
May 1, 2026 25w ago | 3 | $0.6350 $0.6810 | ▲ +7.24% | ▲ +1.60% | — |
Mar 13, 2026 32w ago | Press Release | $0.6290 $0.5500 | ▲ +12.56% | ▲ +16.15% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers